GMAB Stock Overview
Develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GMAB from our risk checks.
Genmab A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | DKK 1,553.50 |
52 Week High | DKK 2,283.00 |
52 Week Low | DKK 1,530.00 |
Beta | 0.86 |
11 Month Change | -12.55% |
3 Month Change | -16.10% |
1 Year Change | -25.24% |
33 Year Change | -46.94% |
5 Year Change | 10.45% |
Change since IPO | 566.74% |
Recent News & Updates
The Price Is Right For Genmab A/S (CPH:GMAB)
Sep 19We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated
Aug 22Recent updates
The Price Is Right For Genmab A/S (CPH:GMAB)
Sep 19We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated
Aug 22Genmab A/S' (CPH:GMAB) Price In Tune With Earnings
Apr 02We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope
Mar 07Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings
Feb 21Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?
Nov 13Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?
Jun 19Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?
May 29With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case
Mar 18Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate
Feb 27Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching
Dec 17Shareholder Returns
GMAB | DK Biotechs | DK Market | |
---|---|---|---|
7D | -3.1% | -1.5% | 0.3% |
1Y | -25.2% | 3.8% | 14.8% |
Return vs Industry: GMAB underperformed the Danish Biotechs industry which returned -2.2% over the past year.
Return vs Market: GMAB underperformed the Danish Market which returned 14% over the past year.
Price Volatility
GMAB volatility | |
---|---|
GMAB Average Weekly Movement | 3.5% |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 4.4% |
10% most volatile stocks in DK Market | 9.0% |
10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: GMAB has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: GMAB's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 2,526 | Jan G.J. de Winkel | www.genmab.com |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
Genmab A/S Fundamentals Summary
GMAB fundamental statistics | |
---|---|
Market cap | DKK 98.66b |
Earnings (TTM) | DKK 5.54b |
Revenue (TTM) | DKK 19.02b |
17.8x
P/E Ratio5.2x
P/S RatioIs GMAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GMAB income statement (TTM) | |
---|---|
Revenue | DKK 19.02b |
Cost of Revenue | DKK 580.00m |
Gross Profit | DKK 18.44b |
Other Expenses | DKK 12.90b |
Earnings | DKK 5.54b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
Earnings per share (EPS) | 87.24 |
Gross Margin | 96.95% |
Net Profit Margin | 29.13% |
Debt/Equity Ratio | 0% |
How did GMAB perform over the long term?
See historical performance and comparison